Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Boehringer Ingelheim10,821 enrolled

Overview

Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data regarding adverse events.

Study Type

OBSERVATIONAL

Enrollment

10,821

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

SpirivaDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with COPD * Smoker at start Exclusion Criteria: * Patients presenting with any general and specific contraindications listed in the Patient Information Leaflet ('Gebrauchsinformation') and the Basic Product Information('Fachinformation')

Outcomes

Primary Outcomes

Changes in health related quality of life

Time frame: 6 weeks

Secondary Outcomes

Occurrence of Adverse events

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.